Trial Profile
A retrospective study to evaluate safety and efficacy of endostatin in treatment of advanced lung squamous cell carcinoma.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 14 Jun 2017
Price :
$35
*
At a glance
- Drugs Endostatin (Primary)
- Indications Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- 14 Jun 2017 New trial record
- 06 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology